

ENTYVIO (VEDOLIZUMAB) PATIENT REFERRAL AND PRESCRIPTION SHEET

Patient Information						
Patient Name:				Date:		
DOB:				Height:		🗆 inches 🛛 cm
Allergies:				Weight:		🗆 lbs 🖵 kg
Primary Diagnosis						
Diagnosis	ICD-10 Diagnosis					ICD-10
Adult Ulcerative Colitis (UC)	K51.90 Goderate to			o Severe Crohn's Disease		К50.01
Gother:						
Medication Order						
IV Regimen Initial dose: Infuse 300mg IV over at least 30 min on Weeks 0,2 and 6 Maintenance Dose: Infuse 300mg IV over at least 30 min every 8 weeks Other						
Ancillary Orders						
 Pre-medications: Diphenhydramine: 25mg PO 30 min pre-infusion Acetaminophen: 650mg PO 30 min pre-infusion Famotidine: 20 mg PO x1 dose Other pre-meds:			 IV Flush Orders: Peripheral: NS 1-3 mL before/after use Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush Refill x one year 			
Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr						
Therapy Specific Documentation			Other Required Documentation			
CDAI Index Score QuantiFERON-TB Gold			 Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. H&P OR progress note(s) Medication List (include prior/failed DMARDS, biologics, or steroid use) 			
Provider Information						
Provider Name:				Provider Phone:		
Provider NPI:			Provider Fax:			
Provider Address:						

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature:

Date: ____

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.